Aarkstore Market Research Report - Frontier Pharma: Prostate Cancer - Identifying and Commercializing First-in-Class Innovation
The prostate cancer pipeline is among the largest in the pharmaceutical industry with 484 products in active development across all stages. For More Details: http://goo.gl/cIMtf5
The prostate cancer pipeline is among the largest in the pharmaceutical industry with 484 products in active development across all stages.
For More Details: http://goo.gl/cIMtf5
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
<strong>Aarkstore</strong> <strong>Market</strong> <strong>Research</strong> <strong>Report</strong> - <strong>Frontier</strong> <strong>Pharma</strong>:<br />
<strong>Prostate</strong> <strong>Cancer</strong> - <strong>Identify<strong>in</strong>g</strong> <strong>and</strong> <strong>Commercializ<strong>in</strong>g</strong><br />
<strong>First</strong>-<strong>in</strong>-<strong>Class</strong> <strong>Innovation</strong><br />
To buy this <strong>Report</strong> Visit<br />
http://www.aarkstore.com
Discounted <strong>Market</strong> <strong>Research</strong> <strong>Report</strong>s available on <strong>Aarkstore</strong>.com<br />
Offer valid till 28 th February, 2015<br />
For more <strong>in</strong>quiries, contact at +91 9987295242 / 022-27564953<br />
Email: enquiry@aarkstore.com<br />
To buy this <strong>Report</strong> Visit<br />
http://www.aarkstore.com
Summary<br />
Exceptionally Large <strong>and</strong> Innovative Pipel<strong>in</strong>e<br />
The prostate cancer pipel<strong>in</strong>e is among the largest <strong>in</strong> the pharmaceutical<br />
<strong>in</strong>dustry with 484 products <strong>in</strong> active development across all stages. The range of<br />
mechanisms of action employed by these compounds is also highly diverse,<br />
especially <strong>in</strong> comparison to the exist<strong>in</strong>g market l<strong>and</strong>scape. More pert<strong>in</strong>ently, the<br />
degree <strong>and</strong> proportion of breakthrough <strong>in</strong>novations <strong>in</strong> this pipel<strong>in</strong>e is<br />
exceptional; GBI <strong>Research</strong> analysis identified 174 first-<strong>in</strong>-class programs <strong>in</strong> the<br />
prostate cancer pipel<strong>in</strong>e, act<strong>in</strong>g on 122 first-<strong>in</strong>-class molecular targets. This<br />
accounts for some 36% of all products with a disclosed molecular target <strong>and</strong> is<br />
reflective of the high degree of <strong>in</strong>novation <strong>in</strong> this <strong>in</strong>dication. This has farreach<strong>in</strong>g<br />
strategic implications for all market participants, as, despite the high<br />
attrition rate <strong>in</strong> prostate cancer, it is highly likely many of the first-<strong>in</strong>-class<br />
technologies will reach the market over the com<strong>in</strong>g decade <strong>and</strong> may transform<br />
the cl<strong>in</strong>ical <strong>and</strong> commercial l<strong>and</strong>scape.
Summary<br />
Alignment of <strong>First</strong>-<strong>in</strong>-<strong>Class</strong> Molecular Target with Disease Causation<br />
One of the key trends <strong>in</strong> oncology <strong>and</strong> <strong>in</strong> prostate cancer <strong>in</strong> particular over the<br />
last decade is the cl<strong>in</strong>ical <strong>and</strong> commercial impact of targeted therapies designed<br />
to target prote<strong>in</strong>s <strong>in</strong> signal<strong>in</strong>g pathways that are strongly associated with disease<br />
progression. By align<strong>in</strong>g the molecular targets for therapeutic <strong>in</strong>tervention with<br />
disease causation <strong>and</strong>/or propagation, these therapies limit the systemic<br />
cytotoxic effects whilst <strong>in</strong>hibit<strong>in</strong>g tumor-promot<strong>in</strong>g signal<strong>in</strong>g pathways. Such<br />
strategies thereby typically achieve superior efficacy <strong>and</strong> safety profiles.
Summary<br />
A Deals L<strong>and</strong>scape with Numerous Investment Opportunities<br />
Analysis has confirmed that 169 of the 174 first-<strong>in</strong>-class products have not been<br />
<strong>in</strong>volved <strong>in</strong> a licens<strong>in</strong>g or co-development deal. Although many act on targets<br />
that are not yet strongly substantiated <strong>in</strong> terms of their therapeutic potential <strong>in</strong><br />
prostate cancer <strong>in</strong> cl<strong>in</strong>ical studies, there are many which are supported by<br />
promis<strong>in</strong>g <strong>in</strong> vivo <strong>and</strong> <strong>in</strong> vitro precl<strong>in</strong>ical evidence, <strong>and</strong> as such are highly<br />
promis<strong>in</strong>g prostate cancer therapies. Indeed, breakthrough <strong>in</strong>novations are<br />
highly desirable as an <strong>in</strong>vestment option.
Scope<br />
The report analyzes <strong>in</strong>novation <strong>in</strong> prostate cancer, <strong>in</strong> the context of the<br />
overall pipel<strong>in</strong>e <strong>and</strong> current market l<strong>and</strong>scape. In addition, it analyzed the<br />
deals l<strong>and</strong>scape surround<strong>in</strong>g first-<strong>in</strong>-class products <strong>in</strong> prostate cancer, <strong>and</strong><br />
p<strong>in</strong>po<strong>in</strong>ts opportunities for <strong>in</strong>-licens<strong>in</strong>g. The report covers <strong>and</strong> <strong>in</strong>cludes -<br />
- A brief <strong>in</strong>troduction to prostate cancer, <strong>in</strong>clud<strong>in</strong>g symptoms,<br />
pathophysiology, <strong>and</strong> overview of pharmacotherapy <strong>and</strong> treatment<br />
algorithms.<br />
- The chang<strong>in</strong>g molecular target l<strong>and</strong>scape between market <strong>and</strong> pipel<strong>in</strong>e<br />
<strong>and</strong> particular focal po<strong>in</strong>ts of <strong>in</strong>novation <strong>in</strong> the pipel<strong>in</strong>e.<br />
- Comprehensive review of the pipel<strong>in</strong>e for first-<strong>in</strong>-class therapies, analyzed<br />
on the basis of stage of development, molecule type <strong>and</strong> molecular target.<br />
- Identification <strong>and</strong> assessment of first-<strong>in</strong>-class molecular targets with a<br />
particular focus on early-stage programs of which cl<strong>in</strong>ical utility has yet to<br />
be evaluated, as well as literature reviews on novel molecular targets.<br />
- Assessment of the licens<strong>in</strong>g <strong>and</strong> co-development deal l<strong>and</strong>scape for<br />
prostate cancer therapies <strong>and</strong> benchmark<strong>in</strong>g of deals <strong>in</strong>volv<strong>in</strong>g first-<strong>in</strong>-class<br />
versus non-first-<strong>in</strong>-class-products.
Reasons To Buy<br />
The report will assist bus<strong>in</strong>ess development <strong>and</strong> enable market<strong>in</strong>g executives<br />
to strategize their product launches, by allow<strong>in</strong>g them to -<br />
- Underst<strong>and</strong><strong>in</strong>g of the focal shifts <strong>in</strong> molecular targets <strong>in</strong> the prostate<br />
cancer pipel<strong>in</strong>e.<br />
- Underst<strong>and</strong><strong>in</strong>g of the distribution of pipel<strong>in</strong>e programs by phase of<br />
development, molecule type <strong>and</strong> molecular target.<br />
- Access a scientific <strong>and</strong> cl<strong>in</strong>ical analysis of first-<strong>in</strong>-class developmental<br />
programs for prostate cancer, benchmarked aga<strong>in</strong>st non-first-<strong>in</strong>-class<br />
targets.<br />
- Access a list of the first-<strong>in</strong>-class therapies potentially open to dealmak<strong>in</strong>g<br />
opportunities<br />
To know more about this report click here:<br />
http://www.aarkstore.com/pharmaceuticals-healthcare/87810/frontierpharma-prostate-cancer-identify<strong>in</strong>g-<strong>and</strong>-commercializ<strong>in</strong>g-first-<strong>in</strong>-class<strong>in</strong>novation
Table of Contents<br />
<strong>Frontier</strong> <strong>Pharma</strong>: <strong>Prostate</strong> <strong>Cancer</strong> - <strong>Identify<strong>in</strong>g</strong> <strong>and</strong><br />
<strong>Commercializ<strong>in</strong>g</strong> <strong>First</strong>-<strong>in</strong>-<strong>Class</strong> <strong>Innovation</strong><br />
Executive<br />
Summary<br />
Cl<strong>in</strong>ical <strong>and</strong><br />
Commercial<br />
L<strong>and</strong>scape<br />
Assessment of<br />
Pipel<strong>in</strong>e Product<br />
<strong>Innovation</strong><br />
<strong>First</strong>-<strong>in</strong>-<strong>Class</strong><br />
Target <strong>and</strong><br />
Pipel<strong>in</strong>e<br />
Program
Price Chart<br />
<strong>Frontier</strong> <strong>Pharma</strong>: <strong>Prostate</strong> <strong>Cancer</strong> - <strong>Identify<strong>in</strong>g</strong> <strong>and</strong><br />
<strong>Commercializ<strong>in</strong>g</strong> <strong>First</strong>-<strong>in</strong>-<strong>Class</strong> <strong>Innovation</strong><br />
Product Price :<br />
License Type<br />
Price<br />
PDF $ 6695<br />
Site License $ 13990<br />
Enterprise Wide Licence $ 20985<br />
To View OR Purchase <strong>Report</strong>:<br />
Click Here
Related <strong>Market</strong> <strong>Research</strong> <strong>Report</strong><br />
Generic Drugs <strong>Market</strong> <strong>in</strong> Japan 2015-2019<br />
Lung <strong>Cancer</strong>-Global API Manufacturers, <strong>Market</strong>ed <strong>and</strong> Phase III<br />
Drugs L<strong>and</strong>scape, 2015<br />
Metastatic Bra<strong>in</strong> Tumor-Global API Manufacturers, <strong>Market</strong>ed<br />
<strong>and</strong> Phase III Drugs L<strong>and</strong>scape, 2015<br />
Lupus Erythematosus-Global API Manufacturers, <strong>Market</strong>ed <strong>and</strong><br />
Phase III Drugs L<strong>and</strong>scape, 2015<br />
Metastatic Breast <strong>Cancer</strong>-Global API Manufacturers, <strong>Market</strong>ed<br />
<strong>and</strong> Phase III Drugs L<strong>and</strong>scape, 2015<br />
Malaria-Global API Manufacturers, <strong>Market</strong>ed <strong>and</strong> Phase III<br />
Drugs L<strong>and</strong>scape, 2015
Metastatic Colorectal <strong>Cancer</strong>-Global API Manufacturers,<br />
<strong>Market</strong>ed <strong>and</strong> Phase III Drugs L<strong>and</strong>scape, 2015<br />
Melanoma-Global API Manufacturers, <strong>Market</strong>ed <strong>and</strong> Phase III<br />
Drugs L<strong>and</strong>scape, 2015<br />
Metastatic Hormone Refractory (Castration Resistant, Androgen-<br />
Independent) <strong>Prostate</strong> <strong>Cancer</strong>-Global API Manufacturers,<br />
<strong>Market</strong>ed <strong>and</strong> Phase III Drugs L<strong>and</strong>scape, 2015<br />
Men<strong>in</strong>gitis-Global API Manufacturers, <strong>Market</strong>ed <strong>and</strong> Phase III<br />
Drugs L<strong>and</strong>scape, 2015<br />
<strong>Pharma</strong>ceuticals & Healthcare <strong>Market</strong> <strong>Research</strong> <strong>Report</strong>s
About <strong>Aarkstore</strong> Enterprise<br />
• <strong>Aarkstore</strong> Enterprise provides Industry <strong>and</strong> <strong>Market</strong> Analysis <strong>and</strong> <strong>Research</strong><br />
<strong>Report</strong> with expertise <strong>and</strong> technology knowledge on bus<strong>in</strong>ess improvement <strong>and</strong><br />
market acquisition.<br />
• <strong>Aarkstore</strong> achieved its debut pad <strong>in</strong> the year 2008 to explore, work on<br />
assignments <strong>and</strong> cater worldwide clients <strong>and</strong> bus<strong>in</strong>ess giants with bus<strong>in</strong>ess<br />
research on trends, markets <strong>and</strong> technologies. The latest set of applications<br />
guarantees active analysis <strong>and</strong> <strong>Market</strong> <strong>Research</strong> underst<strong>and</strong><strong>in</strong>g for budd<strong>in</strong>g<br />
enterpriser <strong>and</strong> consultants to relate <strong>in</strong>dustry ground research.
Contact Us<br />
Office<br />
Office No. - 809, 8th Floor,<br />
B-W<strong>in</strong>g, Mahaavir Icon,<br />
Plot No.- 89 & 90, Sector-15,<br />
CBD-Belapur, Navi Mumbai – 400614,<br />
Maharashtra, India.<br />
Telefax No: +91 22 4127 6660<br />
24/7 Onl<strong>in</strong>e Support: +91 9987295242<br />
General Inquiries : +91 - 22 2756 4953<br />
You Can Visit :<br />
http://www.aarkstore.com<br />
OR Mail us at :<br />
contact@aarkstore.com<br />
Blog :<br />
http://www.aarkstore.com/blog/<br />
Conference :<br />
http://conference.aarkstore.com/<br />
News :<br />
http://www.aarkstore.com/news
Change language